ArticleBioengineered2021

Targeting the miR-6734-3p/ZEB2 axis hampers development of non-small cell lung cancer (NSCLC) and increases susceptibility of cancer cells to cisplatin treatment.

Linying Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.